L-Carnitine and NAFLD (Non-alcoholic fatty liver disease)

Non-alcoholic fatty liver disease (NAFLD) is a common condition among fitness enthusiasts, particularly those with diets high in fats.

Recent studies have highlighted the potential of L-carnitine in managing NAFLD. This post reviews a systematic review and meta-analysis that explores L-carnitine’s efficacy and safety in treating NAFLD.

Study Overview

A systematic review and meta-analysis published in Systematic Reviews included eight randomized controlled trials (RCTs) involving 544 participants. The studies evaluated L-carnitine’s effects on liver function and lipid profiles in NAFLD patients.

Key Findings

  • Improved Liver Function: L-carnitine supplementation significantly improved liver enzyme levels (AST, ALT, γ-GT), indicating better liver function.
  • Enhanced Lipid Profiles: Participants showed improvements in lipid profiles, including increased HDL cholesterol and reduced LDL cholesterol and triglycerides.
  • Dosage and Duration: Effective dosages ranged from 1000 mg to 2000 mg per day, with treatment durations of 12 to 24 weeks showing the most benefits.

Safety and Side Effects

L-carnitine was well-tolerated among participants, with few reported side effects. The most common side effects were mild gastrointestinal issues.

Conclusion

L-carnitine shows promise in managing NAFLD by improving liver function and lipid profiles. Its safe and effective use can be a beneficial addition for those struggling with fatty liver conditions. For more details, refer to the full study here.

Share the Post:

Trusted top producers of Injectable L-Carnitine in North America.

First time visiting our new-look site? Your account has been successfully migrated. Please reset your password here before logging in, by clicking the ‘Forgot Password’ link below:

Welcome back!